AngioDynamics (NASDAQ:ANGO – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
A number of other research firms have also commented on ANGO. Canaccord Genuity Group lifted their price objective on AngioDynamics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, July 13th. Raymond James cut AngioDynamics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the company from $14.00 to $13.00 in a research report on Monday, April 17th.
AngioDynamics Price Performance
NASDAQ ANGO opened at $8.74 on Friday. AngioDynamics has a fifty-two week low of $8.18 and a fifty-two week high of $24.74. The stock’s 50-day moving average is $10.01 and its two-hundred day moving average is $11.08. The firm has a market cap of $342.96 million, a P/E ratio of -6.62 and a beta of 0.62. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.95 and a quick ratio of 1.29.
AngioDynamics (NASDAQ:ANGO – Get Free Report) last released its quarterly earnings results on Wednesday, July 12th. The medical instruments supplier reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. AngioDynamics had a negative net margin of 15.48% and a negative return on equity of 0.61%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $90.73 million. During the same quarter last year, the firm posted $0.01 earnings per share. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, analysts anticipate that AngioDynamics will post -0.33 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new stake in AngioDynamics in the 1st quarter valued at $36,000. CWM LLC raised its holdings in shares of AngioDynamics by 1,048.0% in the 4th quarter. CWM LLC now owns 2,032 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 1,855 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of AngioDynamics by 95.1% during the 1st quarter. Captrust Financial Advisors now owns 2,883 shares of the medical instruments supplier’s stock worth $62,000 after buying an additional 1,405 shares during the period. Quarry LP boosted its stake in AngioDynamics by 227.4% in the 1st quarter. Quarry LP now owns 3,899 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 2,708 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in AngioDynamics by 187.1% in the third quarter. Tower Research Capital LLC TRC now owns 4,442 shares of the medical instruments supplier’s stock valued at $91,000 after acquiring an additional 2,895 shares during the period. 92.82% of the stock is owned by institutional investors.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.